GlassScriptPhysician profile
Nathaniel Edward Wiest
NPI 1215590864
$1,310.20
in general payments reported to CMS, 2019-2025
12 companies · $478 in 2025
The $478 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $330 · 2023: $228 · 2024: $274 · 2025: $478.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $494 · Food and Beverage: $486.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $493.93 |
| Food and Beverage | $486.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $229.98 | 2022-2025 | |
| Ipsen Biopharmaceuticals, INC | $216.22 | 2024-2025 | Onivyde |
| Exelixis INC. | $199.94 | 2023-2024 | |
| Eisai INC. | $123.31 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $115.11 | 2022 | |
| Gilead Sciences, INC. | $105.65 | 2024 | Trodelvy |
| Sanofi-Aventis U.S. LLC | $95.00 | 2023 | |
| G1 Therapeutics, INC. | $84.14 | 2022 | |
| Lilly USA, LLC | $79.44 | 2025 | Verzenio |
| Novartis Pharmaceuticals Corporation | $28.41 | 2024 | |
| Foundation Medicine, INC. | $17.89 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.11 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathaniel Wiest listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.